KANUMA DIN 02469596
Health Canada record
| Active ingredient(s) | SEBELIPASE ALFA 2 MG |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Schedule | PRESCRIPTION; SCHEDULE D |
| Class | Human |
| ATC | A16AB14 SEBELIPASE ALFA |
| Original market date | 05-Apr-2018 |
| Current status date | 05-Apr-2018 |
| Source | Health Canada DPD |
Establishment licence of the holder
Alexion Pharma Canada Corp — licence 101731, currently licensed, last inspection rating C (2026-02-04).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 20164 | 2017-12-15 | New Drug Submission (NDS) |